Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Longeveron reported financial results for the year ended December 31, 2025 and provided a business update. Results from pivotal P2 trial anticipated 3Q26.
-
Longeveron to report 2025 full year financial results and provide a business update on March 17, 2026 after the U.S. financial markets close.
-
Longeveron announces closing of previously announced up to $30 million private placement.
-
Longeveron announces private placement financing of up to $30 million.
-
Results of Phase 2b clinical trial demonstrating stem cell therapy improved condition of patients with aging frailty published in Cell Stem Cell journal.
-
Longeveron (LGVN) has appointed Stephen H. Willard as Chief Executive Officer.
-
Longeveron supports the passing of the Mikaela Naylon Give Kids a Chance Act which reauthorizes the Rare Pediatric Disease Priority Review Voucher Program.
-
Longeveron presents new MRI biomarker data linking neuroinflammation to clinical outcomes in patients with mild Alzheimer's disease at CTAD 2025.
-
Cellular therapy laromestrocel Phase 2 clinical trial data in Alzheimer's disease selected for poster presentation at CTAD 2025.
-
Click here to join the case LOS ANGELES, Oct. 06, 2021 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises investors that a class action lawsuit has been filed on behalf of Longeveron, Inc....